The Lescol® Intervention Prevention Study (LIPS): A double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease

International Journal of Cardiovascular Interventions

Volumn 4, Issue 4, 2001, Pages 165-172

  Serruys, Patrick W J C ^a   De Feyter, Pim J ^a   Benghozi, Renée ^a   Hugenholtz, Paul G ^a   Lesaffre, Emmanuel ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Coronary heart disease; Fluvastatin; Percutaneous transluminal coronary angioplasty; Secondary prevention

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; SIDE EFFECT; SURVIVAL TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035565270     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/14628840127765     Document Type: Article

References (37)

1. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Study (MRFIT)
2. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study
3. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung and Blood Institute
4. Serum cholesterol, blood pressure, cigarette smoking and death from coronary heart disease. Overall findings and differences by age for 316 099 white men
5. Relationship of baseline cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and longevity
6. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
7. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
8. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
9. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
10. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
11. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle aged man with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
12. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study (LCAS)
13. The Lipid Research Clinics Coronary Prevention Trial results II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
14. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial)
15. Second report of the Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults (Adult Treatment Panel III)
16. The effects of lowering serum cholesterol on coronary heart disease risk
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
18. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
19. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial
20. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
21. Comparison between PTCA and bypass operation. Results of large randomized studies
22. Long-term results of RITA-1 trial: Clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised Intervention Treatment of Angina
23. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients
24. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
25. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
26. Ethical principles for medical research involving human subjects
27. Grading of angina pectoris
28. Unstable angina: A classification
29. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge
30. SAS technical report P-229
31. Discrete sequential boundaries for clinical trials
32. A multiple testing procedure for clinical trials
33. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
34. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
35. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy